526 related articles for article (PubMed ID: 24959688)
1. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.
Falagas ME; Tansarli GS; Karageorgopoulos DE; Vardakas KZ
Emerg Infect Dis; 2014 Jul; 20(7):1170-5. PubMed ID: 24959688
[TBL] [Abstract][Full Text] [Related]
2. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
[TBL] [Abstract][Full Text] [Related]
3. Health outcomes attributable to carbapenemase-producing Enterobacteriaceae infections: A systematic review and meta-analysis.
Budhram DR; Mac S; Bielecki JM; Patel SN; Sander B
Infect Control Hosp Epidemiol; 2020 Jan; 41(1):37-43. PubMed ID: 31637986
[TBL] [Abstract][Full Text] [Related]
4. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia.
Borer A; Saidel-Odes L; Riesenberg K; Eskira S; Peled N; Nativ R; Schlaeffer F; Sherf M
Infect Control Hosp Epidemiol; 2009 Oct; 30(10):972-6. PubMed ID: 19712030
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
6. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.
Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N
Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725
[TBL] [Abstract][Full Text] [Related]
7. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
Pang F; Jia XQ; Zhao QG; Zhang Y
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
[TBL] [Abstract][Full Text] [Related]
8. [Clinical, epidemiological and microbiological characterization of bacteremia produced by carbapenem-resistant enterobacteria in a university hospital in Córdoba, Argentina].
Lipari FG; Hernández D; Vilaró M; Caeiro JP; Saka HA
Rev Chilena Infectol; 2020 Aug; 37(4):362-370. PubMed ID: 33399656
[TBL] [Abstract][Full Text] [Related]
9. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.
Balkan II; Aygün G; Aydın S; Mutcalı SI; Kara Z; Kuşkucu M; Midilli K; Şemen V; Aras S; Yemişen M; Mete B; Özaras R; Saltoğlu N; Tabak F; Öztürk R
Int J Infect Dis; 2014 Sep; 26():51-6. PubMed ID: 24998423
[TBL] [Abstract][Full Text] [Related]
10. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.
Satlin MJ; Chen L; Patel G; Gomez-Simmonds A; Weston G; Kim AC; Seo SK; Rosenthal ME; Sperber SJ; Jenkins SG; Hamula CL; Uhlemann AC; Levi MH; Fries BC; Tang YW; Juretschko S; Rojtman AD; Hong T; Mathema B; Jacobs MR; Walsh TJ; Bonomo RA; Kreiswirth BN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167547
[TBL] [Abstract][Full Text] [Related]
12. Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data.
O'Donnell JN; Rhodes NJ; Biehle LR; Esterly JS; Patel TS; McLaughlin MM; Hirsch EB
Int J Antimicrob Agents; 2020 Feb; 55(2):105849. PubMed ID: 31770628
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital.
Souli M; Kontopidou FV; Papadomichelakis E; Galani I; Armaganidis A; Giamarellou H
Clin Infect Dis; 2008 Mar; 46(6):847-54. PubMed ID: 18269335
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
18. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.
Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S
Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425
[TBL] [Abstract][Full Text] [Related]
20. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies.
Zhang Y; Chen XL; Huang AW; Liu SL; Liu WJ; Zhang N; Lu XZ
Emerg Microbes Infect; 2016 Mar; 5(3):e27. PubMed ID: 27004762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
